Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Cosmo reports record 2022 financial results exceeding guidance,
increased dividend by 10%, confirms 2023 guidance
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
LivaNova to Announce First-Quarter 2023 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce First-Quarter 2023 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m

Convatec Group PLC: Annual Report and Accounts 2022 and Notice of AGM
Convatec Group PLC: Annual Report and Accounts 2022 and Notice of AGM
Convatec Group PLC: Annual Report and Accounts 2022 and Notice of AGM
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Convatec Group PLC: Director/PDMR Shareholding
Convatec Group PLC: Director/PDMR Shareholding
Convatec Group PLC: Director/PDMR Shareholding
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program


Novocure (NASDAQ: NVCR) today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for

Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches Apollo™, an Industry-Leading, Secure, Cloud-Based Platform for Real-Time Toxicology Study Data


Charles River Laboratories International, Inc. (NYSE: CRL) today launched Apollo™, an industry-leading, secure, cloud-based platform for drug developers that provides access to study data, study

Premier, Inc. Named One of the 2023 World’s Most Ethical Companies® by Ethisphere® for 16th Consecutive Year: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Named One of the 2023 World’s Most Ethical Companies® by Ethisphere® for 16th Consecutive Year


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical

QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended

Charles River Laboratories to Present at Barclays Global Healthcare Conference: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Present at Barclays Global Healthcare Conference


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 15th, at 10:15 a.m. ET. Management

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Convatec Group PLC: Director/PDMR Shareholding
Convatec Group PLC: Director/PDMR Shareholding
Convatec Group PLC: Director/PDMR Shareholding
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology


LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is

LivaNova to Present at the Barclays Global Healthcare Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present at the Barclays Global Healthcare Conference


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays

Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches Helper Plasmid to Streamline Adeno-Associated Viral Vector Manufacturing


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus

QIAGEN und Servier entwickeln Begleitdiagnostikum für Medikament zur Behandlung der akuten myeloischen Leukämie
QIAGEN und Servier entwickeln Begleitdiagnostikum für Medikament zur Behandlung der akuten myeloischen Leukämie


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine strategische Partnerschaft mit dem globalen Pharmaunternehmen Servier bekannt gegeben. Die Kooperation zielt darauf ab, ein

QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic

Premier Inc. to Participate in Barclays Global Healthcare Conference on March 14, 2023: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. to Participate in Barclays Global Healthcare Conference on March 14, 2023


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Barclays

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc